Funding for this research was provided by:
Received: 22 July 2021
Revised: 20 August 2021
Accepted: 27 August 2021
First Online: 7 September 2021
: Research support by Novartis to AH, PLR, JH. Outside of the study, AS has received consulting fees from AbbVie, Amgen, Celltrion, Janssen, MSD, Mundipharma, and Takeda; lecture fees and support for travel accommodation from AbbVie, Amgen, FalkFoundation, Janssen, MSD, and Takeda; and research funding from Abbvie and Celltrion. Outside of the study, PAR received consulting and lecture fees from CSL Behring, Dr. Wilmar Schwabe, Boston Scientific, Pfizer, and travel grants from Merz Pharma.